Skip to main content

The Scandinavian Propaten® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomised clinical controlled multi-centre trial

Lindholt et al. 20111

Vascular Research Unit, Department of Vascular Surgery, Viborg Hospital, Denmark

Primary patency of GORE® PROPATEN® Vascular Graft

N=112
1 year 81%

Patient characteristics*

Characteristic N %
Smokers 144 53%
Diabetes 39 15%
Critical limb ischemia (CLI) 100 36%

Study details

  • Prospective, randomized, multi-center (11 centers) study comparing GORE® PROPATEN® Vascular Graft versus standard ePTFE
  • Fem-pop (majority above-knee) and fem-fem bypasses
  • Statistically significant improvement in primary and secondary patency with GORE® PROPATEN® Vascular Graft versus standard ePTFE for all bypasses
  • In fem-pop patients with CLI, GORE® PROPATEN® Vascular Graft primary patency was 80% while standard ePTFE patency was 58% (p < 0.05)

We have seen that the GORE® PROPATEN® Vascular Graft keeps its promise as shown in previously conducted prospective and retrospective studies. – J. Lindholt


*GORE® PROPATEN® Vascular Graft group, N = 272,* which includes 160 patients with fem-fem bypass.

1. Lindholt JS, Gottschalksen B, Johannesen N, et al.  The Scandinavian Propaten® trial - 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses - a randomised clinical controlled multi-centre trial.  European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.